Anti-CSl humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu

Blood

Volumn 112, Issue 4, 2008, Pages 1329-1337

  Tai, Yu Tzu ^a,c   Dillon, Myles ^b   Song, Weihua ^a   Leiba, Merav ^a   Li, Xian Feng ^a   Burger, Peter ^a   Lee, Alfred I ^a   Podar, Klaus ^a   Hideshima, Teru ^a   Rice, Audie G ^b   Van Abbema, Anne ^b   Jesaitis, Lynne ^b   Caras, Ingrid ^b   Law, Debbie ^b   Weller, Edie ^c   Xie, Wanling ^c   Richardson, Paul ^a   Munshi, Nikhil C ^a   Mathiot, Claire ^d   Avet Loiseau, Hervé ^e   Afar, Daniel E H ^b   Anderson, Kenneth C ^a,c   more..

^a HARVARD MEDICAL SCHOOL   (United States)

^b PDL BioPharma Inc   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d INSTITUT CURIE   (France)

^e INSTITUT DE BIOLOGIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; HEAT SHOCK PROTEIN 90 INHIBITOR; HULUC63; MEMBRANE PROTEIN; MESSENGER RNA; MONOCLONAL ANTIBODY; PROTEIN CS1; SMALL INTERFERING RNA; SYNDECAN 1; UNCLASSIFIED DRUG; IMMUNOGLOBULIN RECEPTOR; SLAMF7 PROTEIN, HUMAN; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW; CELL ADHESION; CELL SURFACE; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; FEMALE; HUMAN; HUMAN CELL; MOUSE; MULTIPLE MYELOMA; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; TUMOR REGRESSION; XENOGRAFT; ANIMAL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; CELL CULTURE; DRUG EFFECT; DRUG SCREENING; GENETICS; IMMUNOLOGY; PATHOLOGY; STROMA CELL;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, NEOPLASM; BONE MARROW; CELL ADHESION; HUMANS; MICE; MULTIPLE MYELOMA; RECEPTORS, IMMUNOLOGIC; RNA, MESSENGER; STROMAL CELLS; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 51649083849     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2007-08-107292     Document Type: Article

References (34)

1. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005; 352:2487-2498.
2. Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and pred-nisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet. 2006; 367:825-831.
3. Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR. Phase III clinical trial of thalidomide plus dexamethasone compared with dexametha-sone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2006;24:431-436.
4. Richardson PG, Blood E, Mitsiades CS, et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood. 2006;108:3458-3464.
5. Barlogie B, Tricot G, Anaissie E, et al. Thalido-mide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med. 2006;354:1021-1030.
6. Tai YT, Catley LP, Mitsiades CS, et al. Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications. Cancer Res. 2004;64:2846-2852.
7. Tai YT, Li X, Tong X, et al. Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma. Cancer Res. 2005;65:5898-5906.
8. Stein R, Qu Z, Cardillo TM, et al. Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies. Blood. 2004;104:3705-3711.
9. Sapra P, Stein R, Pickett J, et al. Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys. Clin Cancer Res. 2005;11:5257-5264.
10. Tassone P, Gozzini A, Goldmacher V, et al. In vitro and in vivo activity of the maytansinoid im-munoconjugate huN901-N2′-deacetyl-N2′-(3- mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells. Cancer Res. 2004;64:4629-4636.
11. Ozaki S, Kosaka M, Wakahara Y, et al. Humanized anti-HM1.24 antibody mediates myeloma cell cytotoxicity that is enhanced by cytokine stimulation of effector cells. Blood. 1999;93:3922-3930.
12. Hundemer M, Schmidt S, Condomines M, et al. Identification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myeloma. Exp Hematol. 2006;34:486-496.
13. Tassone P, Goldmacher VS, Neri P, et al. Cyto-toxic activity of the maytansinoid immunoconju-gate B-B4-DM1 against CD138+ multiple myeloma cells. Blood. 2004;104:3688-3696.
14. Sekimoto E, Ozaki S, Ohshima T, et al. Asingle-chain Fv diabody against human leukocyte antigen-A molecules specifically induces myeloma cell death in the bone marrow environment. Cancer Res. 2007;67:1184-1192.
15. Yoshio-Hoshino N, Adachi Y, Aoki C, PereboevA, Curiel DT, Nishimoto N. Establishment of a new interleukin-6 (IL-6) receptor inhibitor applicable to the gene therapy for IL-6-dependent tumor. Cancer Res. 2007;67:871-875.
16. Yang J, Qian J, Wezeman M, et al. Targeting beta2-microglobulin for induction of tumor apo-ptosis in human hematological malignancies. Cancer Cell. 2006;10:295-307.
17. Tai YT, Li XF, Breitkreutz I, et al. Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. Cancer Res. 2006;66:6675-6682.
18. Tai YT, Podar K, Catley L, et al. Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3'-kinase/ AKT signaling. Cancer Res. 2003;63:5850-5858.
19. Drobyski WR, Gottlieb M, Carrigan D, et al. Phase I study of safety and pharmacokinetics of a human anticytomegalovirus monoclonal antibody in allogeneic bone marrowtransplantrecipients. Transplantation. 1991;51:1190-1196.
20. Tai YT, Li XF, Catley L, et al. Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicityin human multiple myeloma: clinical implications. Cancer Res. 2005;65:11712-11720.
21. Moffat J, Grueneberg DA, Yang X, et al. Alentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell. 2006;124:1283-1298.
22. Tai YT, Podar K, Kraeft SK, et al. Translocation of Ku86/Ku70 to the multiple myeloma cell membrane: functional implications. Exp Hematol. 2002;30:212-220.
23. The Institute of Laboratory Animal Resources, National Research Council: Guide for the Care and Use of Laboratory Animals. Washington, DC: National Institutes of Health, publication no. 86-23.
24. Boles KS, Mathew PA. Molecular cloning of CS1, a novel human natural killer cell receptor belonging to the CD2 subset of the immunoglobulin su-perfamily. Immunogenetics. 2001;52:302-307.
25. Boles KS, Stepp SE, Bennett M, Kumar V, Mathew PA. 2B4 (CD244) and CS1: novel members of the CD2 subset of the immunoglobulin superfamily molecules expressed on natural killer cells and other leukocytes. Immunol Rev. 2001; 181:234-249.
26. Murphy JJ, Hobby P, Vilarino-Varela J, et al. A novel immunoglobulin superfamily receptor (19A) related to CD2 is expressed on activated lymphocytes and promotes homotypic B-cell adhesion. Biochem J. 2002;361:431-436.
27. Hsi ED, Steinle R, Balasa B, et al. CS1: a potential newtherapeutic targetfor the treatmentof multiple myeloma. Blood. 2006;108:3457.
28. Bprset M, Hjertner O, Yaccoby S, Epstein J, Sanderson RD. Syndecan-1 is targeted to the uropods of polarized myeloma cells where it promotes adhesion and sequesters heparin-binding proteins. Blood. 2000;96:2528-2536.
29. Hazlehurst LA, Foley NE, Gleason-Guzman MC, et al. Multiple mechanisms confer drug resistance to mitoxantrone in the human 8226 myeloma cell line. Cancer Res. 1999;59:1021-1028.
30. Law CL, Gordon KA, Collier J, et al. Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40. Cancer Res. 2005;65:8331-8338.
31. Kumaresan PR, Lai WC, Chuang SS, Bennett M, Mathew PA. CS1, a novel member of the CD2 family, is homophilic and regulates NK cell function. Mol Immunol. 2002;39:1-8.
32. Stark S, Watzl C. 2B4 (CD244), NTB-A and CRACC (CS1) stimulate cytotoxicity but no proliferation in human NK cells. Int Immunol. 2006;18:241-247.
33. Davies FE, Raje N, HideshimaT, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood. 2001;98:210-216.
34. Tai YT, Fulciniti M, Hideshima T, et al. Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis. Blood. 2007;110:1656-1663.